Northwest Biotherapeutics Seeks Antigen Deal To Avoid Folding
About one month after saying it would suspend recruitment in a Phase III trial of its lead prostate cancer drug, sell some fixed assets and consider other options for the future, Northwest Biotherapeutics Inc. has made more cuts and may shut down entirely. (BioWorld Today)
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.